数位基因组市场规模、份额、成长分析、按产品、按应用、按最终用户、按地区 - 按行业预测，2024-2031 年

2022年全球数位基因组市场规模为255亿美元，从2023年的294亿美元成长到2031年的918.3亿美元，预测期内（2024-2031年）复合年增长率为15.3。

在基因组和生物资讯技术进步的推动下，全球数位基因组市场正在经历强劲成长。最近的分析显示市场规模和成长潜力显着扩大，反映了不断变化的趋势和竞争格局。这种快速成长的主要驱动力是次世代定序仪(NGS) 技术的日益普及。次世代定序仪能够提供快速且经济高效的 DNA 和 RNA 定序，彻底改变了基因组学。随着 NGS 相关成本持续下降，基因组定序变得越来越容易实现，从而导致产生的基因组资料量显着增加。这种可访问性可能会鼓励数位基因组学领域的进一步创新和应用，从而实现持续发展。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 抑制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2023）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析

数位基因组市场规模：依产品分类

• 市场概况
• 定序和分析设备
• DNA/RNA分析套件
• 定序晶片
• 定序和分析软体
• 样品製备设备

数位基因组市场规模：依应用分类

• 市场概况
• 临床
• 生殖健康
• 肿瘤学
• 其他的
• 法医学
• 药物发现与开发
• 其他用途

数位基因组市场规模：依最终用户划分

• 市场概况
• 医院
• 诊断中心和法医学实验室
• 调查机构
• 其他最终用户

数位基因组市场规模：按地区划分

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2023）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2021-2023）

主要企业简介

• Illumina, Inc.（USA）
• 23andMe, Inc.（USA）
• BGI Genomics Co., Ltd.（China）
• Thermo Fisher Scientific（USA）
• Agilent Technologies（USA）
• Danaher Corporation（USA）
• Oxford Nanopore Technologies plc.（United Kingdom）
• PacBio（USA）
• QIAGEN（Netherlands）
• Roche Holding AG（Switzerland）
• Myriad Genetics, Inc.（USA）
• Invitae Corporation（USA）
• Color Genomics（USA）
• Sema4（USA）
• Veritas Genetics（USA）
• Helix（USA）
• 24Genetics（Spain）
• Dante Genomics（Italy）
• Gencove（USA）
• Nebula Genomics（USA）

结论和建议

Global Digital Genome Market size was valued at USD 25.5 billion in 2022 and is poised to grow from USD 29.4 billion in 2023 to USD 91.83 billion by 2031, growing at a CAGR of 15.3% during the forecast period (2024-2031).

The global digital genome market is experiencing robust growth, propelled by advancements in genomics and bioinformatics technologies. Recent analyses indicate a considerable expansion in market size and growth potential, reflecting evolving trends and the competitive landscape. A significant driver behind this surge is the rising adoption of next-generation sequencing (NGS) technologies, which have transformed genomics through their ability to deliver rapid, cost-effective DNA and RNA sequencing. As the costs associated with NGS continue to decline, genomic sequencing has become increasingly accessible, resulting in a substantial increase in genomic data generation. This accessibility is likely to foster further innovations and applications within the digital genome sector, positioning it for continued advancement.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Digital Genome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Digital Genome Market Segmental Analysis

Global Digital Genome Market is segmented by product, application, end user and region. Based on product, the market is segmented into sequencing and analyzer instruments, DNA/RNA analysis kits, sequencing chips, sequencing and analysis software and sample preparation instruments. Based on application, the market is segmented into clinical, reproductive health, oncology, others, forensics, drug discovery and development and other applications. Based on end user, the market is segmented into hospitals, diagnostic centers and forensic labs, research institutes and other end users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Digital Genome Market

The global digital genome market is significantly driven by the rising incidence of genetic disorders, which underscores the urgent need for efficient solutions that facilitate accurate diagnosis and timely intervention. As genetic disorders become more prevalent, digital genome technologies are gaining prominence for their ability to provide precise genetic testing, screening, and diagnosis. These advancements enable healthcare professionals to detect genetic conditions early, implement preventive measures, and offer targeted treatments, thereby improving patient outcomes and fostering a proactive approach to healthcare. The demand for such innovative tools is growing rapidly, highlighting the importance of digital genome solutions in modern medicine.

Restraints in the Global Digital Genome Market

The Global Digital Genome market faces several significant restraints, particularly concerning ethical and legal issues. The collection and use of genomic data bring forth complexities surrounding data ownership, informed consent, and the risk of discrimination against individuals. It is essential to navigate these challenges thoughtfully to ensure that ethical considerations do not hinder innovation. Achieving a harmonious balance between promoting technological advancements and addressing these critical ethical concerns will be vital for the sustainable development of the digital genome market. Without careful attention to these restraints, the market's growth may be jeopardized, limiting its potential benefits for society.

Market Trends of the Global Digital Genome Market

The Global Digital Genome market is witnessing significant growth, primarily driven by the rapid adoption of next-generation sequencing (NGS) technologies. These advanced sequencing tools offer unparalleled speed, accuracy, and cost-effectiveness, making genomic analysis accessible to a broader audience, including academic institutions, healthcare providers, and biotechnology companies. As the demand for personalized medicine and targeted therapies increases, organizations are increasingly leveraging NGS for applications in genomics research, clinical diagnostics, and drug development. Moreover, the integration of artificial intelligence and big data analytics in genomic data interpretation is further propelling market expansion, positioning the digital genome sector at the forefront of biotechnological innovation.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Digital Genome Market Size by Product & CAGR (2024-2031)

• Market Overview
• Sequencing and Analyzer Instruments
• DNA/RNA Analysis Kits
• Sequencing Chips
• Sequencing and Analysis Software
• Sample Preparation Instruments

Global Digital Genome Market Size by Application & CAGR (2024-2031)

• Market Overview
• Clinical
• Reproductive Health
• Oncology
• Others
• Forensics
• Drug Discovery and Development
• Other Applications

Global Digital Genome Market Size by End User & CAGR (2024-2031)

• Market Overview
• Hospitals
• Diagnostic Centers and Forensic Labs
• Research Institutes
• Other End Users

Global Digital Genome Market Size & CAGR (2024-2031)

• North America (Product, Application, End User)
  • US
  • Canada
• Europe (Product, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Illumina, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• 23andMe, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BGI Genomics Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxford Nanopore Technologies plc. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PacBio (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Invitae Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Color Genomics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sema4 (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Veritas Genetics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Helix (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• 24Genetics (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dante Genomics (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gencove (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nebula Genomics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations